Author: [email protected]

Bimergen Energy (BESS) – Powering Up a 2 GW Opportunity

Posted on by [email protected]


Thursday, October 29, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Richard Magnusen, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating coverage with an Outperform rating. Bimergen Energy develops, finances, owns, and operates utility-scale battery energy storage systems (BESS). The company has assembled 23 development projects representing approximately 2.0 gigawatts (GW) of capacity across several regional U.S. power markets. We believe the portfolio provides a range of options to unlock value as Bimergen advances projects through development, monetization, financing, construction, and ultimately commercial operation.

Multiple paths to value creation. Bimergen can monetize projects by retaining minority interests alongside strategic partners or owning completed assets and generate recurring operating revenue. The company has begun demonstrating this flexibility through the sale of the 100-megawatt (MW) Redbird project and two smaller ERCOT projects to Frontier Power while retaining a 7.5% economic interest. We believe this transaction provides initial evidence that development-stage projects can create tangible value before commercial operation.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NN (NNBR) – First Look at 3Q26 Results

Posted on by [email protected]


Thursday, October 29, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Quarterly Overview. NN delivered a strong 3Q26, significantly exceeding our expectations for sales, adjusted EBITDA, and adjusted net income. NN’s new business program has continued to outperform expectations, with the Company now winning more than 1 new program per day. And NN’s 5 Pillar growth program is working well, with the Company investing its time and resources to strategically pivot the portfolio to high-growth, high-value markets and products.

3Q26 Numbers. Net sales for 3Q26 were $131.1 million, an increase of 26.2% compared to net sales of $103.9 million for 3Q25. The increase was primarily driven by higher selling prices, higher volumes, and favorable foreign exchange effects.  Adjusted EBITDA was $18.5 million, an increase of 49.7% compared to adjusted EBITDA of $12.4 million for the same period in 2025. Adjusted net income was $5.3 million, or $0.07 per diluted common share, an increase of $5.6 million or $0.08 per diluted common share, y-o-y.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Fed Holds Interest Rates at 3.75%–4.00% as Two Officials Push for Hike Amid Persistent Inflation

Posted on by [email protected]

The Federal Reserve held interest rates steady Wednesday, October 28, maintaining its benchmark federal funds rate at 3.75% to 4.00% as policymakers weighed resilient economic growth against persistent inflation pressures. The widely anticipated decision followed September’s quarter-percentage-point rate increase and revealed a notable division among central bank officials over whether additional tightening is needed.

The Federal Open Market Committee voted 10–2 to leave rates unchanged, with Federal Reserve Governor Lisa Cook and Cleveland Fed President Beth Hammack dissenting in favor of another 25-basis-point increase. The split underscores growing concerns among some policymakers that inflation remains too elevated to justify a prolonged pause in monetary tightening.

In its official statement, the Federal Reserve acknowledged that inflation remains elevated while emphasizing the need for additional economic data before determining its next policy move. The central bank reiterated its commitment to returning inflation to its 2% target, signaling that further rate increases remain possible.

The decision comes after the Fed raised interest rates in September for the first time in more than three years. That move marked a shift toward tighter monetary policy as higher energy prices, persistent consumer spending, and broader price pressures complicated efforts to control inflation.

Recent economic data illustrate the challenge. Consumer prices rose 3.7% year over year in September, remaining well above the Fed’s target. Elevated energy costs have contributed to inflation, while price increases across other goods and services suggest that pressures are extending beyond fuel markets.

Despite those concerns, the Federal Reserve delivered a more optimistic assessment of overall economic activity. Policymakers described the economy as expanding at a strong pace, an upgrade from the characterization of solid growth used at their September meeting.

The statement highlighted resilient domestic spending, strong productivity growth, and robust capital investment. Officials also noted that job gains have generally kept pace with growth in the labor force, while the unemployment rate has changed relatively little.

This combination of economic strength and persistent inflation creates a difficult balancing act. Raising interest rates further could help reduce price pressures, but additional tightening would also increase borrowing costs for businesses and consumers.

For small-cap companies, the Fed’s decision carries particular significance. Smaller publicly traded businesses often depend more heavily on external financing than large corporations with substantial cash reserves and established access to capital markets.

Higher interest rates can increase the cost of refinancing debt, limit expansion opportunities, and reduce investor appetite for companies that require additional capital to fund operations.

Emerging biotechnology companies may be especially sensitive to these conditions because clinical development frequently requires significant funding before products generate commercial revenue. Small industrial manufacturers, technology companies, and consumer businesses can also face pressure from higher financing expenses and slower customer spending.

The Russell 2000 Index, which tracks smaller publicly traded U.S. companies, remains an important benchmark for investors assessing how changes in monetary policy influence the small-cap market.

The Fed’s decision also has implications for the housing market. Mortgage rates have climbed above 7% in recent weeks, weighing on affordability even as home prices continue rising in many parts of the country. Although mortgage rates are not directly set by the Federal Reserve, they are influenced by Treasury yields and expectations for future monetary policy.

Attention now turns to the Fed’s final scheduled policy meeting of 2026 in December. Investors have increasingly considered the possibility of another rate increase before year-end, particularly if inflation remains stubbornly above the central bank’s target.

Federal Reserve Chair Kevin Warsh’s post-meeting remarks will be closely examined for additional insight into how officials are evaluating inflation, economic growth, and the timing of potential future policy changes.

Wednesday’s decision leaves borrowing costs unchanged for now, but the dissenting votes and the Fed’s continued emphasis on price stability suggest that the debate over further tightening is far from settled.

For investors, particularly those focused on smaller companies, the direction of interest rates over the coming months could play a significant role in determining financing conditions, equity valuations, and market sentiment heading into 2027.

DoorDash Nears $17 Billion Instacart Acquisition as Delivery Giants Look to Challenge Amazon and Walmart

Posted on by [email protected]

DoorDash (NASDAQ: DASH) is reportedly in advanced negotiations to acquire grocery delivery platform Instacart (NASDAQ: CART) in a deal that could value the company at approximately $17 billion, potentially creating one of the largest combined food and grocery delivery platforms in the United States.

According to reports from The Wall Street Journal and Reuters, an agreement could be announced as soon as this week, although negotiations remain ongoing and there is no guarantee a transaction will be completed. The potential acquisition would represent a significant expansion of DoorDash’s business beyond restaurant delivery as competition intensifies across the online grocery and retail markets.

Investors responded sharply to news of the negotiations. Instacart shares climbed approximately 8% on Monday, while DoorDash stock declined roughly 6%, reflecting enthusiasm about a potential takeover premium alongside concerns about the cost and complexity of the acquisition.

Before reports of a possible sale emerged, Instacart had a market capitalization of approximately $12 billion. A transaction valued at $17 billion would represent a substantial premium and mark one of the more significant technology acquisitions of 2026.

The proposed combination would bring together two major players with complementary strengths. DoorDash has established an extensive delivery network through its restaurant business and expanded into convenience stores, grocery chains, and general merchandise retailers. Instacart, meanwhile, specializes in grocery shopping and delivery, maintaining established relationships with supermarket operators and providing technology that supports online ordering and retail advertising.

Together, the companies could offer consumers a broader range of delivery options while creating opportunities to consolidate logistics, improve delivery efficiency, and expand advertising services.

The strategic motivation comes as traditional delivery platforms face increasing competition from Amazon and Walmart, both of which have invested heavily in grocery fulfillment, same-day delivery, and customer loyalty programs.

DoorDash already works with retailers including Kroger, Safeway, Aldi, CVS, Macy’s, and Target. Acquiring Instacart could deepen its relationships with grocery chains and accelerate its efforts to become a comprehensive local commerce platform rather than primarily a restaurant delivery service.

For Instacart, the potential transaction comes after several years of adjusting to slower growth following the pandemic-driven surge in online grocery shopping. The company went public in 2023 but has faced mounting competitive pressure from larger technology platforms and retailers developing their own digital ordering capabilities.

Instacart has also expanded beyond delivery into advertising and software services for retailers, businesses that could become important components of DoorDash’s longer-term growth strategy.

However, the financial implications of a potential acquisition remain uncertain. The companies have not disclosed a proposed transaction structure, including whether the purchase would be financed through cash, stock, or a combination of both.

Analysts have also raised questions about whether the potential cost savings and additional revenue opportunities would justify the reported acquisition price. Integrating two large delivery networks could create efficiencies, but overlapping operations, technology systems, and retail partnerships may present challenges.

Regulatory scrutiny represents another consideration. Because DoorDash and Instacart compete in portions of the grocery delivery market, a combination could attract attention from antitrust regulators evaluating its potential impact on competition, merchants, and consumers.

The reported negotiations follow an earlier attempt by DoorDash to acquire Instacart in 2021, when the grocery delivery company’s private-market valuation was considerably higher. Those discussions ultimately failed to produce an agreement.

Uber Technologies (NYSE: UBER) also reportedly explored acquiring Instacart, although those discussions are no longer active.

The potential deal underscores a broader shift in the delivery industry, where companies are increasingly pursuing acquisitions, operational efficiencies, and diversified revenue streams as growth becomes more competitive.

For investors, the key questions will be whether DoorDash can translate greater scale into improved profitability, how much it must pay to secure Instacart, and whether regulators would approve the combination.

If completed, the acquisition could significantly reshape the competitive landscape for online grocery delivery, creating a larger challenger to Amazon and Walmart while accelerating consolidation across the digital commerce industry.

Travelzoo (TZOO) – Membership Momentum Sets Up 2027 Earnings Growth

Posted on by [email protected]


Wednesday, October 28, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

George Proost, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Investment weighs on Q3. Revenue increased 3% to $22.9 million, in line with expectations. Adjusted EBITDA fell to a loss of $2.2 million, modestly wider than our estimated loss of $1.5 million. The earnings shortfall largely reflected higher sales and marketing expenditures associated with the company’s transition to a paid membership model. 

Membership growth accelerates. Club Members increased 65% year over year, supported by $5.8 million in direct membership acquisition spending during the quarter. Encouragingly, average U.S. customer acquisition cost fell to $54 from $62 in the second quarter, while deferred revenue rose to $13.5 million, providing greater visibility into future recurring membership revenue.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

T3 Defense (DFNS) – A New Acquisition

Posted on by [email protected]


Wednesday, October 28, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Acquisition. T3 Defense has entered into a definitive agreement to acquire KeepZone AI from Nexera Technologies. KeepZone expands T3’s offerings into the Homeland Security vertical. The acquisition allows T3 to expand its commercial reach while providing the Company with a U.S. presence and active channels in North America, Latin America, and the Gulf. We view the proposed acquisition as another building block in T3’s efforts to build a mission-critical defense business embedded at critical chokepoints.

Details. Initial consideration is $1.0 million, payable in common stock (and, to the extent required by a 4.9% beneficial ownership limitation, pre-funded warrants), priced at the average closing price of T3 Defense common stock for the five trading days preceding closing. Nexera is also eligible for an earn-out equal to 50% of KeepZone’s standalone net profit generated during the 24 months following the closing, calculated on the first $10.0 million of net profit and therefore capped at $5.0 million, payable in cash. Closing is expected within 60 days.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

U.S. Home Prices Rise Again as Mortgage Rates Above 7% Threaten Housing Market Recovery

Posted on by [email protected]

U.S. home prices continued climbing in August, signaling persistent pressure on housing affordability even before mortgage rates surged above 7%, according to new data released Tuesday. The latest figures highlight the challenges facing prospective homebuyers and raise questions about whether the housing market can maintain its momentum through the final months of 2026.

The S&P Cotality Case-Shiller 20-City Composite Home Price Index increased 2.65% year over year in August, accelerating from a 2.47% gain in July. The broader National Home Price Index rose 2.09% annually, up from approximately 1.9% the previous month.

Although home prices continue to appreciate, the pace remains below overall inflation. Consumer prices increased 3.4% in August, meaning housing values declined in inflation-adjusted terms for the 15th consecutive month.

The figures suggest that the U.S. housing market is experiencing a gradual adjustment rather than a widespread decline in property values. However, affordability remains a major obstacle for buyers already facing elevated home prices, borrowing costs, and household expenses.

According to the National Association of Realtors, the median existing-home price reached $429,100 in August, the highest recorded for that month. Even modest price increases can create additional challenges for first-time buyers struggling to accumulate down payments and qualify for mortgages.

The latest Case-Shiller report also reflects transactions completed between June and August, before the sharp increase in mortgage rates that followed. That timing is particularly important because financing conditions have deteriorated considerably since late summer.

The average rate on a 30-year fixed mortgage climbed to 7.40% in mid-October before easing slightly to 7.32% during the week ending October 22, according to Freddie Mac. That compares with 6.19% a year earlier.

For prospective homeowners, the difference can significantly affect monthly payments and purchasing power. Higher borrowing costs reduce the amount buyers can afford to finance, potentially weakening demand even when housing inventory improves.

Regional housing trends also reveal a market moving in different directions. Chicago recorded the strongest annual price appreciation among major metropolitan areas, with home values rising 6.7%. New York followed with a 6.2% increase, while Cleveland posted a 4.3% gain.

Other markets experienced declines. Seattle home prices fell 2.0% from a year earlier, while Las Vegas and Denver also registered annual decreases.

These differences reflect varying levels of housing supply, local economic conditions, and buyer demand. Markets with limited inventory have generally demonstrated greater pricing resilience, while areas experiencing weaker demand have faced more downward pressure.

Separate data from the Federal Housing Finance Agency reinforced the broader trend. U.S. single-family home prices increased 0.3% in August compared with July and rose 2.4% from a year earlier.

Despite the annual gains, the Case-Shiller national index declined 0.2% month over month on a non-seasonally adjusted basis, suggesting that housing market momentum remains uneven.

For investors, the combination of high mortgage rates and slower home price appreciation has implications across several industries, including homebuilding, construction materials, mortgage lending, and real estate services.

Homebuilders may face increased pressure to offer price reductions or mortgage-rate incentives to attract buyers. Mortgage lenders and real estate brokerages could also experience weaker transaction volumes as affordability constraints discourage purchases and refinancing activity.

The Federal Reserve’s interest rate outlook adds another layer of uncertainty. Although mortgage rates are not directly determined by the central bank, they are heavily influenced by Treasury yields, inflation expectations, and broader monetary policy.

With the Fed scheduled to announce its latest policy decision Wednesday, investors will be watching for signals about whether borrowing costs could remain elevated into 2027.

The August housing data ultimately presents a mixed picture. Home prices continue to rise in nominal terms, but inflation-adjusted values are declining, regional markets are diverging, and higher mortgage rates threaten to weaken buyer demand.

For the housing market, the next test will be whether improving inventory and moderating price growth can offset borrowing costs that remain near multiyear highs.

Release – Century Lithium Sets Date For 2026 Annual General Meeting And Announces Director Slate And New Nominee Dr. Cormac O’Laoire

Posted on by [email protected]

October 27, 2026 – Vancouver, Canada – Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) (“Century Lithium” or the “Company”) is pleased to announce its Annual General Meeting of Shareholders (the “Meeting”) will be held on November 25, 2026. During the Meeting, the management will nominate five directors for election to the Company’s Board of Directors (the “Board”), Dr. Corby Anderson, Dr. William Willoughby, Donald Myers, James Pettit and Dr. Cormac O’Laoire, who stands for election for the first time. Bryan Disher is retiring from the Board and will not stand for re-election; he will continue to serve as a director through the conclusion of the Meeting.

Dr. O’Laoire has worked closely with management as a Strategic Advisor since January 2026, and his depth in battery materials, gigafactory execution and lender due diligence bears directly on the decisions ahead as Century Lithium moves Angel Island through permitting and into project finance.

The Board would like to thank Mr. Disher for his many contributions to Century Lithium and for his continued service through the Meeting.

New Director Nominee

Cormac O’Laoire, PhD is Managing Director of Electrios Ltd., a Hong Kong-based battery advisory firm, and has served as Strategic Advisor to Century Lithium since January 2026. He has over 20 years of experience across the lithium-ion battery value chain, from battery metals and lithium refining through precursor and cathode active materials (pCAM/CAM), cell manufacturing, energy storage and recycling.

Based in Hong Kong for more than a decade, Dr. O’Laoire has advised automakers, cell manufacturers, materials suppliers, governments, lenders, and investors on battery manufacturing, materials processing and battery energy storage projects, providing technical due diligence, lenders’ technical advisory, capital-cost review and independent oversight for more than 60 GWh of capacity. He is also a retained expert witness in industrial litigation and international arbitration.

Dr. O’Laoire began his career in electrochemical research, including as a Postdoctoral Fellow at Lawrence Berkeley National Laboratory, a US Department of Energy national laboratory, and his doctoral research on lithium-air battery chemistry is widely cited. He holds a PhD in Physical Chemistry from Northeastern University in Boston, Massachusetts.

Information concerning the Meeting and the procedures for voting will be included in the Company’s Notice of Meeting and Management Information Circular, which will be filed under the Company’s profile on SEDAR+ in advance of the Meeting. Shareholders are encouraged to review the meeting materials when available and to vote their shares.

ABOUT CENTURY LITHIUM CORP.

Century Lithium Corp. is an advanced-stage lithium development company focused on its 100%-owned Angel Island Lithium Project in Esmeralda County, Nevada. Angel Island hosts one of the largest known sedimentary lithium deposits in the United States and is designed with an integrated, end-to-end process to produce battery-grade lithium carbonate on-site to support the electric vehicle and battery storage markets.

The Company has developed a patent-pending process that incorporates hydrochloric acid leaching combined with direct lithium extraction to produce battery-grade lithium carbonate. As part of the integrated chlor-alkali process, Angel Island is designed to produce sodium hydroxide as a co-product, with planned surplus sales expected to lower operating costs, reduce reliance on externally sourced reagents, and minimize environmental impacts.

Century Lithium is currently advancing Angel Island through the permitting process.

Century Lithium trades on the TSX Venture Exchange under the symbol “LCE”, the OTCQX under the symbol “CYDVF” and on the Frankfurt Stock Exchange under the symbol “C1Z”. To learn more, please visit centurylithium.com.

ON BEHALF OF CENTURY LITHIUM CORP.
WILLIAM WILLOUGHBY, PhD, PE
President & Chief Executive Officer
For further information, please contact:
Spiros Cacos | Vice President, Investor Relations
Direct: +1 604 764 1851
Toll Free: 1 800 567 8181
[email protected]
centurylithium.com

Release – As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated – Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides

Posted on by [email protected]

Shelton, Connecticut – Tuesday, October 27, 2026.


NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), a clinical stage leader
developing antiviral drugs that viruses cannot escape, explained today that the Phase IIA Ebola Treatment
Clinical Trial of NV-387 Oral Gummies is progressing well, and the drug is expected to advance into the
Phase IIB clinical trial part as soon as the Phase IIA part is completed.

“The importance of the NV-387 Oral Gummies treatment for this Ebola Bundibugyo virus disease
cannot be understated, considering the potential of the disease for rapid spread and the heavy toll it is
taking in affected areas in terms of both deaths and economic costs of containment and response,” said
Anil R. Diwan, PhD, President and Executive Chairman of the Company.

The NV-387 Oral Gummies as a Treatment for Ebola Phase II Clinical Trial in DRC is divided
into two parts. The first part, Phase IIA, is designed to evaluate dosing regimens based on the severity of
the disease, and requires approximately 20 patients. Enrollment began on September, 23, 2026. The end
point is 28-day survival, as with other Ebola clinical trials. As such, the Phase IIA part will be completed
once the last enrolled person completes 28 days.

The course of the clinical trial suggests that the trial will continue into Phase IIB part upon completion of
the Phase IIA part.

Ebola has escaped the main epidemic affected country of Democratic Republic Congo (DRC) in
multiple instances, and cases have started occurring in Kenya as well as Nigeria, one of the most
populous countries in Africa . Previously, an infected person had traveled from DRC to Uganda, causing 1
a small outbreak, but there have been no new cases reported in Uganda recently. A person that traveled
recently from DRC to Kenya died, and infected at least 8 others, one of whom has also died, and at least
134 contacts were traced . Kenya has released some of the quarantined contacts. The case in Nigeria was 2
a Swiss national and was evacuated to a Swiss hospital for treatment. Previously, medical personnel
working with the Doctors Without Borders (MSF/DWB) have been evacuated to Europe for treatment.

This East to West Africa spread has occurred in spite of substantive travel restrictions. Additional
restrictions have been effected by many countries as a result . Importantly, the instances of single 3
infected persons creating multiple cases have demonstrated the significant global risk and challenge posed
by this Ebola outbreak. As many as 8 or more cases have occurred from contact with a single infected
person during this outbreak. Such persons causing a large number of transmissions are often called
“superspreaders”.

As the outbreak continues, the number of confirmed cases in DRC have reached 10,060, with
4,887 deaths since this Ebola-Bundibugyo virus outbreak was identified. It is the fastest growing Ebola
outbreak, and largest in DRC, with the potential to eclipse, in a few months, the West Africa 2014-16
Ebola-Zaire outbreak that killed 11,000 people.

A clinical trial of Infusions of an antibody cocktail, Infusion of remdesivir, and Infusion of both
of them given to the patient is in progress, called the “PARTNERS” clinical trial, since July 2, 2026.
There have been no public updates, other than that more than 350 patients were already enrolled about a
month ago.

A clinical trial to evaluate vaccines, called “Tumaini” (meaning “Hope” in Swahili) has started as
of last week. The first candidate vaccine in this trial is Ervebo, which is specific to Ebola Zaire, and it is
not known how effective it could be against Ebola Bundibugyo virus. Two other vaccine candidates, one
developed by University of Oxford, ChAdOx1-BDBV, and another, a BDBV-mRNA vaccine developed
by Moderna, are expected to be added into this clinical trial when the supplies become available . This 4
vaccines trial will employ a “ring vaccination” protocol.

Ervebo vaccine is not specific to BDBV, which means it is an unmatched vaccine. Unmatched
Page 1 of 4vaccines can cause rapid occurrence of escape mutants. Also, in vaccinated persons, later infection can
even cause a more aggressive disease, a phenomenon called “Antibody-Dependent Enhancement” of
disease, promoted by the inaccurate antibodies created in response to the vaccine. Vaccines in general can
lead to escape mutants. Ebola virus is an RNA virus and thus very capable of generating escape mutants.
Vaccines are not useful for a person after infection. Also, a vaccine requires about 2-3 weeks for
antibody response to be generated, and therefore is minimally protective before 3 weeks. If a second dose
of vaccine is needed, it complicates the situation further, because the first dose only creates partial
immunity.

Thus an effective treatment is essential for combatting a spreading epidemic such as the current
Ebola epidemic. Infusions such as of antibody cocktails or small chemical drugs are only useful, if
effective, when patients can be hospitalized for the duration until recovery, and are costly to store,
transport, and administer. Thus, to combat a widely spreading disease in the community, oral drugs are the
most preferred.

There is no treatment or vaccine approved for Ebola BDBV at present. NV-387 Oral Gummies is
the only oral drug product in clinical trials, to the best of our knowledge, underscoring its importance for
fighting the current Ebola BDBV epidemic, and future epidemics.
The same drug product, NV-387 Oral Gummies, is also in a Phase II clinical trial for the
treatment of Mpox (Monkeypox) in DRC.

NV-387 is a novel, revolutionary broad-spectrum antiviral that is poised to change the way
humanity treats viral infections.

ABOUT NANOVIRICIDES
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating
special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates
and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of
TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development
of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar
diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several
licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from
TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment
of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox
infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot
project an exact date for filing an IND for any of its drugs because of dependence on a number of external
collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical
trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate
remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir
encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA
approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable.
Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and
NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital
Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal
Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform
technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour
licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several
drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases:
Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes
Page 2 of 4Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue
viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The
Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful.
As is customary, the Company must state the risk factor that the path to typical drug development of any
pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts
by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would
show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this
time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful
pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation
regarding future events. Actual events could differ materially and substantially from those projected herein and
depend on a number of factors. Certain statements in this release, and other written or oral statements made by
NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forwardlooking statements since they involve known and unknown risks, uncertainties and other factors which are, in some
cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no obligation to publicly update or revise these
forward-looking statements for any reason, or to update the reasons actual results could differ materially from those
anticipated in these forward-looking statements, even if new information becomes available in the future. Important
factors that could cause actual results to differ materially from the company’s expectations include, but are not
limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the
company from time to time with the United States Securities and Exchange Commission and other regulatory
authorities. Although it is not possible to predict or identify all such factors, they may include the following:
demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful
development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to
the indications we are seeking; the successful commercialization of our product candidates; and market acceptance
of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research
findings including clinical trials as the customary research usage and do not indicate evaluation of safety or
effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug”
application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and
Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines
Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”.
WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
[email protected]
Public Relations Contact:
[email protected]
Source: NanoViricides, Inc.

Release – Enterprises Empower AI Agents for Bounded Tasks

Posted on by [email protected]

10/27/2026

STAMFORD, Conn.–(BUSINESS WIRE)– Enterprises are using agentic AI to redistribute work between people and machines, giving it defined operational responsibilities while keeping humans in the loop, according to two new global research reports published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm.

The 2026 ISG Provider Lens® Agentic AI Services report finds that the technical capabilities of agents are progressing faster than companies are delegating responsibility to them. In most organizations, it is more common for agentic AI platforms to coordinate and perform defined tasks than to independently own consequential processes. This measured approach reflects concerns about accountability, permissions, security and operational risk in areas where technology can alter records or trigger actions.

“Organizations are focusing on work that intelligent platforms can perform reliably within defined limits,” said Steve Hall, chief AI officer, ISG. “The goal is allocation of responsibility between machines and people, with safeguards that preserve accountability for consequences. With clear operating conditions, companies can delegate responsibility to AI without exceeding acceptable business limits.”

The 2026 ISG Provider Lens® Agentic AI Services — Specialists report finds that specialist providers are advancing from isolated task agents toward multi-step workflows and multi-agent orchestration. They are industrializing delivery through libraries of reusable agents and embedding governance controls throughout the lifecycle of an agent rather than treating governance as a checkpoint.

Before assigning responsibilities to agents, enterprises are assessing whether decisions are bounded, outcomes are observable and exceptions are manageable. Multi-step processes with clear operating parameters are the strongest candidates for giving AI greater agency. The objective is to reduce human effort and handoffs across workflows while shortening cycle times and making organizations more responsive.

As more responsibility is delegated to AI agents, humans’ roles are shifting toward validation, approvals, exception handling and supervision. Authentication, audit trails, thresholds and escalation paths establish the conditions for permitting actions by agents and determining when responsibility returns to people. Enterprises are imposing rules and policy constraints to limit unexpected results. While 79 percent of enterprises plan to increase AI technology spending, improved governance is the most significant change companies say they would make based on their experience so far, ISG says.

“The real measure of agentic AI is not an individual agent’s sophistication, but its ability to move work forward reliably across the enterprise,” said Gowtham Kumar Sampath, ISG principal analyst and lead author of the report. “That requires dependable connections among systems, clear responsibilities and outcomes that can be observed at each step of a workflow.”

The reports also explore other trends in agentic AI services, including the increasing importance of validation, recovery and escalation when actions produce unexpected results and the growing demand for controls on agent access to tools, applications and data.

For more insights into the agentic AI-related challenges faced by enterprises, along with ISG’s advice for addressing them, see the ISG Provider Lens Focal Points briefing here.

The Agentic AI Services report evaluates 60 large and midsize providers across two quadrants: Agentic AI Development and Deployment Services — Large Providers and Agentic AI Development and Deployment Services — Midsize Providers.

The report names Accenture, Accion Labs, Apexon, Ascendion, Atos, Birlasoft, Brillio, Capgemini, Cognizant, Cybage, DXC Technology, EXL, Firstsource, HCLTech, Hexaware, IBM, Infosys, Konecta, NTT DATA, Persistent Systems, Softtek, Sutherland, TCS, Trigent, Unisys and Virtusa as Leaders in one quadrant each.

In addition, Genpact and HTC Global Services are recognized as Rising Stars — companies with a “promising portfolio” and “high future potential” by ISG’s definition — in one quadrant each.

The Agentic AI Services― Specialists report evaluates 21 providers in one quadrant: Agentic AI Development and Deployment — Specialist Providers.

The report names 66degrees, Fractal Analytics, Lingaro, Network Science, Quantiphi, Straive, Tiger Analytics, Tredence and Version 1 as Leaders in the quadrant.

In addition, Sigmoid is recognized as a Rising Star — a company with a “promising portfolio” and “high future potential” by ISG’s definition — in the quadrant.

In the area of customer experience, HCLTech, Persistent Systems and 66Degrees are named the global ISG CX Star Performers for 2026 among large, midsize and specialist Agentic AI Services providers, respectively. HCLTech, Persistent Systems and 66Degrees earned the highest customer satisfaction scores in ISG’s Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry.

Customized versions of the reports are available from Accion Labs, Akkodis, Ascendion, Atos, DXC Technology, EXL, Firstsource, Hexaware, Mindsprint, Orion Innovation, Tiger Analytics, Tredence, Unisys, Version 1 and Virtusa.

The 2026 ISG Provider Lens Agentic AI Services report is available to subscribers or for one-time purchase on this webpage. The Agentic AI Services — Specialists report is available here.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.Source: Information Services Group, Inc.

Release – T3 Defense Enters Agreement to Acquire KeepZone AI

Posted on by [email protected]

Oct 27, 2026

NEW YORK and NETANYA, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) — T3 Defense Inc. (Nasdaq: DFNS) (“T3 Defense” or the “Company”), a defense company that acquires and operates mission-critical defense businesses, today announced that it has entered into a definitive stock purchase agreement to acquire 100% of KeepZone AI Inc. (“KeepZone”), a homeland security technology distribution, integration, and marketing company, from Nexera Technologies Ltd. (Nasdaq: NEXR) (“Nexera”). Following the closing, KeepZone is expected to serve as T3 Defense’s dedicated homeland security (HLS) marketing, sales and business development platform, extending the Company’s commercial reach to critical infrastructure, law enforcement, public safety, and border security customers in Israel and international markets.

T3 Defense Inc.

KeepZone adds a dedicated sales and business development capability to T3 Defense’s portfolio of engineering and manufacturing subsidiaries, bringing an experienced business development team, a U.S.-incorporated commercial entity, and representation agreements with homeland security technology providers that allow it to offer customers integrated, multi-layer security solutions. T3 Defense intends to use KeepZone’s sales channels to introduce its subsidiaries’ products alongside KeepZone’s existing portfolio, creating cross-selling opportunities and a broader offering for customers.

KeepZone markets, distributes, and integrates technologies for both its proprietary VocentraAI voice-analysis platform and products from its partners, including Scanary, SeeTrue, STI, RT LTA Systems, BeeSense, ParaZero, ZorroNet, VELQOR, SensorzTech and Skyline Software Systems. KeepZone combines these capabilities into coordinated security solutions for critical infrastructure and other homeland security applications.

“Our subsidiaries build mission-critical defense systems; KeepZone brings a dedicated sales platform to introduce those products to additional homeland security customers,” said Menny Shalom, Chairman and Chief Executive Officer of T3 Defense. “This acquisition will allow us to expand our commercial reach while providing us with a U.S. presence and active channels in North America, Latin America and the Gulf. We structured the transaction so that a majority of the potential consideration is contingent on KeepZone generating post-closing net profit, aligning the acquisition with our disciplined approach to capital allocation.”

“KeepZone was built to connect homeland security technologies with the customers who need them,” said Alon Dayan, Chief Executive Officer of KeepZone. “Joining T3 Defense adds a portfolio of engineered defense products that we can bring to our customer and partner relationships, so we can offer them a broader, integrated solution set from a single partner.”

Transaction Details

Initial consideration is $1.0 million, payable at closing in newly issued common stock (and, to the extent required by a 4.9% beneficial ownership limitation, pre-funded warrants), priced at the average closing price of T3 Defense common stock for the five trading days preceding closing. Nexera is also eligible for an earn-out equal to 50% of KeepZone’s standalone net profit generated during the 24 months following the closing, calculated on the first $10.0 million of net profit and therefore capped at $5.0 million, payable in cash. The seller is also entitled to additional shares of T3 Defense common stock if 6 months after closing the stock price is less than the price on closing. KeepZone is being acquired without any debt or liability. Closing is expected within 60 days of the signing of the stock purchase agreement, subject to customary closing conditions, including Nasdaq notification regarding the issuance of additional shares and certain third-party consents. Additional details will be included in a Current Report on Form 8-K to be filed with the Securities and Exchange Commission (SEC).

About KeepZone AI Inc.
KeepZone AI Inc. is a homeland security technology company that markets, integrates and supports a multi-vendor portfolio of screening, surveillance, counter-UAS, AI analytics and unmanned aerial solutions for critical infrastructure, government and high-security environments. For more information, visit www.KeepZone.ai.

About T3 Defense Inc.
T3 Defense Inc. (Nasdaq: DFNS) is a defense company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with strong customer relationships and solid order backlogs, often capacity- and resource-constrained, in specialized areas such as drones and autonomous vehicles, counter-drone systems, advanced manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and strategy, and decentralized day-to-day operations, T3 Defense aims to strengthen essential defense capabilities and build long-term value. For more information, visit www.t3dfns.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the anticipated closing and timing of the acquisition of KeepZone; the expected benefits of the acquisition, including cross-selling and commercial opportunities; the potential earn-out; KeepZone’s representation and distribution relationships; and the Company’s growth and acquisition strategy. These statements are based on management’s current expectations and involve risks and uncertainties that could cause actual results to differ materially, including: the risk that closing conditions, including Nasdaq notification and third-party consents, are not satisfied or that the transaction does not close; the risk that KeepZone’s representation or distribution agreements are terminated, not renewed or not consented to; the absence of any assurance that KeepZone will generate revenue or profit or that any earn-out will become payable; dilution from the issuance of shares and warrants; integration risks; defense and homeland security procurement timing and funding; customer concentration; competitive and geopolitical conditions, including conditions in Israel; the Company’s liquidity and capital resources; the Company’s ability to maintain compliance with Nasdaq listing requirements; and other risks described in the Company’s filings with the SEC, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update or revise them, except as required by law.

Contact Us:
T3 Defense Inc.
575 5th Avenue
New York, NY 10017
[email protected]
www.t3dfns.com

Investor Relations
The Equity Group Inc.
Lena Cati
[email protected]
+1 212 836-9611

Val Ferraro
[email protected]
+1 212 836-9633

Release – Lucky Strike Entertainment Completes Transition of Bowlmor Locations to Lucky Strike

Posted on by [email protected]

10/27/2026

Bowlmor Cupertino becomes Lucky Strike Cupertino, carrying forward the legacy of the brand that started it all

RICHMOND, Va.–(BUSINESS WIRE)– Lucky Strike Entertainment (NYSE: LUCK), one of the world’s premier owner-operators of location-based entertainment destinations, announced today that Bowlmor Cupertino has been rebranded as Lucky Strike Cupertino, marking the transition of the company’s final operating Bowlmor location. The milestone celebrates the brand that first turned bowling into a night out and marks the next chapter for a company that continues to grow as more people rediscover the lanes. The new Lucky Strike Cupertino location arrives just in time for holiday party season, giving Bay Area companies, teams and groups a new destination for year-end celebrations.

Bowlmor Lanes opened in New York City’s Greenwich Village in the 1930s and became a beloved neighborhood institution. In 1997, Thomas Shannon acquired Bowlmor and reimagined what a bowling center could be, adding upscale food and cocktails, music, lighting, and lounge-style lanes. The concept invented bowling as entertainment, turning a classic pastime into a pop culture hotspot complete with A-listers such as Sarah Jessica Parker, Jimmy Fallon, and Al Pacino. That vision became the foundation for Lucky Strike Entertainment’s growth into a company with more than 360 locations across North America, spanning bowling, amusements, water parks, and family entertainment centers. It’s fitting that Bowlmor’s final chapter unfolds in Cupertino, a city known worldwide for reinventing entire categories. Today, Lucky Strike carries Bowlmor’s spirit and Shannon’s vision forward in every center.

“Bowlmor is where it all began. We set out to prove that bowling could be the best day or night out in the city, and that idea has grown into something bigger than we ever imagined,” said Thomas Shannon, Founder and CEO of Lucky Strike Entertainment. “Bringing Bowlmor Cupertino under the Lucky Strike name isn’t an ending. It’s a celebration of everything Bowlmor started and a sign of how much bowling continues to grow.”

The rebrand comes as bowling enjoys renewed momentum, with league participation rising every year and nearly 70M people bowling on average each year. Lucky Strike Cupertino offers guests state-of-the-art bowling lanes, elevated food and beverage options, a vibrant arcade and immersive Bay Area entertainment experiences, including holiday parties and group celebrations.

For more information on Lucky Strike Cupertino, visit LuckyStrikeEnt.com, or follow along on social at @luckystrikeent. For information on parties and packages, visit here.

About Lucky Strike Entertainment:
Lucky Strike Entertainment is one of the world’s premier location-based entertainment platforms. With over 360 locations across North America, Lucky Strike Entertainment provides experiential offerings in bowling (Lucky Strike, Bowlero, AMF), amusements, water parks, and family entertainment centers. The company also owns the Professional Bowlers Association, the major league of bowling and a growing media property that boasts millions of fans around the globe. For more information on Lucky Strike Entertainment, please visit IR.LuckyStrikeEnt.com.

Media:
[email protected]

Source: Lucky Strike Entertainment Corporation

Fed Rate Decision Wednesday: Why Small-Cap Stocks Face a Critical Test as Inflation Pressures Build

Posted on by [email protected]

The Federal Reserve is preparing to announce its latest interest rate decision Wednesday, October 28, as investors assess whether persistent inflation and elevated borrowing costs could create additional challenges for U.S. stocks, particularly smaller companies that depend heavily on access to capital.

The Federal Open Market Committee began its two-day policy meeting Tuesday, with economists broadly expecting policymakers to maintain the benchmark federal funds rate at its current range of 3.75% to 4.00%. While an immediate rate increase appears unlikely, attention is shifting toward the central bank’s outlook for December and whether inflation could require additional monetary tightening.

The upcoming announcement arrives at a sensitive moment for financial markets. Inflation remains above the Federal Reserve’s 2% target, while higher energy prices and persistent price pressures have complicated expectations for the direction of interest rates.

For investors, the most important development may not be Wednesday’s decision itself, but what Federal Reserve Chair Kevin Warsh communicates about the central bank’s willingness to keep borrowing costs elevated or raise rates further.

Market expectations currently favor an unchanged policy rate this week. However, interest rate futures indicate investors are assigning considerably greater probability to an increase at the Fed’s December meeting, underscoring concerns that inflation may remain difficult to control.

The prospect of sustained higher interest rates carries particular significance for small-cap companies. Unlike many large corporations with substantial cash reserves and established access to debt markets, smaller businesses frequently depend on bank financing, revolving credit facilities, and capital markets to support expansion and operations.

Higher interest rates can increase debt servicing expenses, reduce profitability, and make new investment projects more expensive. Companies with significant refinancing requirements may face additional pressure as existing debt matures and must be replaced at higher borrowing costs.

These conditions can also influence equity valuations. When Treasury yields rise, investors may demand higher returns from riskier assets, potentially placing downward pressure on stocks with earnings expected further into the future.

The Russell 2000 Index, a widely followed benchmark for smaller publicly traded U.S. companies, is particularly sensitive to changes in financing conditions and expectations for economic growth.

For emerging biotechnology companies, elevated interest rates can make equity financing more challenging and increase the importance of maintaining sufficient cash to fund clinical trials and regulatory development. Smaller industrial and consumer businesses may face a different combination of pressures, including financing expenses, higher input costs, and changes in customer demand.

Meanwhile, companies in energy and materials must balance borrowing costs against the effects of commodity prices, which can influence both revenue expectations and inflation trends.

The Federal Reserve’s decision also comes as longer-term Treasury yields remain elevated. The benchmark 10-year Treasury yield has approached 5%, adding pressure to borrowing costs across the economy, including mortgages and corporate financing.

Wednesday’s announcement could therefore influence investor sentiment even if policymakers leave the benchmark rate unchanged. A statement emphasizing persistent inflation or the possibility of further tightening could push Treasury yields higher, while signs of greater confidence in inflation moderation could provide some relief to rate-sensitive sectors.

Investors will also monitor any disagreements among Federal Reserve officials, particularly whether policymakers favoring tighter monetary policy signal growing concern about inflation.

For small-cap investors, the central question is whether the Federal Reserve can bring inflation under control without creating additional financial strain for businesses that rely on affordable c